Log in to save to my catalogue

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched...

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ee095627571b4e258e1890f77d3d7597

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

About this item

Full title

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2022-06, Vol.13 (1), p.3607-3607, Article 3607

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in homologous recombination-deficient models. In this multicentre phase I trial in patients with solid tumors, 40 patients are treated across 10 dose levels (50–650 mg/m
2
) to determine the recommended phase II dose (primary outcome), and evaluate safety, tolerability, ph...

Alternative Titles

Full title

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ee095627571b4e258e1890f77d3d7597

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ee095627571b4e258e1890f77d3d7597

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-022-31199-2

How to access this item